For the quarter ending 2025-03-31, NKGN made $26,241K in revenue. $15,350K in net income. Net profit margin of 58.50%.
| Income Statement | 2025-03-31 | |||
|---|---|---|---|---|
| Research and development expenses | 1,857 | |||
| General and administrative expenses | 2,809 | |||
| Total cost and expenses | 4,666 | |||
| Loss from operations | -4,666 | |||
| Interest expense (including related party amounts of 237 and 698 for the three months ended march 31, 2025 and 2024, respectively) | 509 | |||
| Loss on issuance of financial instruments (including related party amounts of zero and 74 for the three months ended march 31, 2025 and 2024, respectively) | -1,050 | |||
| Gain on amendments to financial instruments, net | 0 | |||
| Change in fair value of financial instruments (including related party amounts of 1,041 and zero for the three months ended march 31, 2025 and 2024, respectively) | 21,575 | |||
| Other loss, net | 0 | |||
| Total other income (expense) | 20,016 | |||
| Net income (loss) before provision for income taxes | 15,350 | |||
| Provision for income taxes | 0 | |||
| Net income (loss) | 15,350 | |||
| Basic (in shares) | 45,962,049 | |||
| Basic (in usd per share) | 0.33 | |||
| Diluted (in shares) | 102,654,719 | |||
| Diluted (in usd per share) | -0.04 | |||
NKGen Biotech, Inc. (NKGN)
NKGen Biotech, Inc. (NKGN)